Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable

Định dạng: PDF / Số trang: 10

Nhắn tin với admin nếu không tải được